


Val-Cit-PAB-MMAE

Cat. No.:	HY-100374
CAS No.:	644981-35-1
Molecular Formula:	C ₅₈ H ₉₄ N ₁₀ O ₁₂
Molecular Weight:	1123.43
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	4°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.	



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 110 mg/mL (97.91 mM) * "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		0.8901 mL	4.4507 mL	8.9013 mL
		5 mM		0.1780 mL	0.8901 mL	1.7803 mL
		10 mM		0.0890 mL	0.4451 mL	0.8901 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5.5 mg/mL (4.90 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (4.45 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (4.45 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
IC ₅₀ & Target	Auristatin

CUSTOMER VALIDATION

-
- Patent. US20210093733A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA